Contact Us

Making the connection: gut dysbiosis, allergy and synbiotics

 

A deeper understanding of the essential role of the gut microbiome – the community of bacteria that inhabit the gut – in health and disease is changing how we think about cows’ milk protein allergy (CMPA).

NUAL22525W-Syneo-Landing-Page-Assets-v1a3.jpg

Immunity and gut dysbiosis

70–80% of immune cells reside in the gut.1 A balanced gut microbiota is associated with a healthy immune system that protects against pathogens and provides tolerance to potential allergens.2–4
Find out more
NUAL22525W-Syneo-Landing-Page-Assets-v1a5.jpg

Gut dysbiosis and CMPA

Infants with CMPA tend to have lower levels of beneficial bacteria and higher levels of harmful bacteria in their gut microbiota compared with healthy, breast-fed infants.5–8 This imbalance in gut microbiota (gut dysbiosis) is linked to an increased risk of allergies and infections in early life.9–11
Find out more
NUAL22525W-Syneo-Landing-Page-Assets-v1a7.jpg

CMPA and synbiotics

The focus of CMPA management has shifted from allergen avoidance to supporting healthy immune response via modulation of the gut microbiota.12 Addition of synbiotics – a synergistic combination of pre- and probiotics – to infant formula has shown to help rebalance the gut microbiota and support immune system development.8,13,14
Find out more
NUAL22525W-Syneo-Landing-Page-Assets-v1a9.jpg

Clinical benefits of SYNEO™

 

SYNEO™ is the only CMPA range to contain a unique, patented blend of pre- and probiotics, inspired by components of breast milk, that work together to help promote a healthy gut microbiota and support immune system development.14–17

 
Find out more

In clinical trials involving infants with CMPA, addition of SYNEO™ demonstrated:13–16,18,19

NUAL22525W-Syneo-Microbiota-276x260-1.jpg

Rebalancing of the gut microbiota closer to healthy breastfed infants

NUAL22525W-Syneo-Antibiotic-276x260.jpg.jpg

Fewer reports of infections and antibiotic use

NUAL22525W-Syneo-Ashtma-276x260.jpg.jpg

Fewer reports of asthma-like symptoms and need for asthma medicine after 1 year

Discover how the SYNEO™ range could make a difference to your patients with CMPA

724x1024-10389684_Neocate-Syneo-212x300.png

Neocate® SYNEO™

A nutritionally complete, amino acid based, powdered infant formula for special dietary use, with a unique blend of ingredients including short- and long-chain FOS (fructo-oligosaccharides) and Bifidobacterium breve M16V. Available on PBS.

View product Request product for evaluation
Aptamil-AllerProSyneo-Stage-1-212x300.png

Aptamil® AllerPro SYNEO™ Infant Formula (0-6 months)

A nutritionally complete, premium extensively hydrolysed formula (eHF) for infants from birth (0–6 months) with confirmed mild to moderate cows’ milk (not anaphylaxis) and/or soy protein allergy, requiring a partial or complete breast milk substitute.

View product Request product for evaluation
Aptamil-AllerProSyneo-Stage-2-212x300.png

Aptamil® AllerPro SYNEO™ 2 (6-12 months)

A premium extensively hydrolysed formula (eHF) for infants with confirmed mild to moderate cows’ milk (not anaphylaxis) and/or soy protein allergy, requiring a partial or complete breast milk substitute as part of a mixed diet.

View product Request product for evaluation

1. Vighi G et al. Clin Exp Immunol. 2008;153(Suppl 1):3–6.
2. Azad M et al. Clin Exp Allergy 2015;45:632–43.
3. Kirjavainen P et al. Gut 2002;51:51–5.
4. Mitsuoka T. Biosci Microbiota Food Health 2014;33:99–116.
5. Roger LC et al. Microbiology 2010;156:3329–41.
6. Abrahamsson TR et al. J Allergy Clin Immunol 2012;129:434–40.
7. Harvey BM et al. Pediatr Res 2014;75:343–51.
8. Candy DCA et al. Pediatr Res 2018;83:677–86.
9. West CE et al. J Allergy Clin lmmunol 2015;135:3–1.
10. Kim BJ et al. Allergy Asthma lmmunol Res 2014;6:389–400.
11. Azad MD et al. BJOG 2016;123:983-93.
12. Sackesen C et al. Front Pediatr 2019;7:372.
13. Van der Aa LB et al. Clin Exp Allergy 2010;40:795–804.
14. Fox AT et al. Clin Transl Allergy 2019;9:5.
15. Jeurink PV et al. Benef Microbes 2013;4:17–30.
16. Scholtens PAMJ et al. J. Annu Rev Food Sci Technol 2012;3:425–447.
17. Martin R et al. Benef Microbes 2010;1(4)367–82.
18. Burks A et al. Pediatr Allergy lmmunol 2015;26:316-22.
19. Chatchatee P et al. J Allergy Clin Immunol 2021; doi; 10.1016/j.jaci.2021.06.025 [Epub ahead of print].

 Nutricia products are intended for the nutritional management of diseases and related medical conditions and therefore should be used under medical supervision.

x